Predictive Oncology Inc. (USD) Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Predictive Oncology Inc. (USD) Active

2915 Commers Drive, Pittsburgh, MN, US, 55121

Stock Price USD

Price Change

Last Dividend USD

C+

Latest Rating

POAI's stock peer is BNGO (Bionano Genomics, Inc.)

POAI's stock peer is DXR (Daxor Corporation)

POAI's stock peer is GCTK (GlucoTrack, Inc.)

POAI's stock peer is GMVD (G Medical Innovations Holdings Ltd)

POAI's stock peer is ISRG (Intuitive Surgical, Inc.)

POAI's stock peer is LUCY (Innovative Eyewear, Inc.)

POAI's stock peer is MBOT (Microbot Medical Inc.)

POAI's stock peer is MLSS (Milestone Scientific Inc.)

POAI's stock peer is NXGL (NEXGEL, Inc.)

POAI's stock peer is PDEX (Pro-Dex, Inc.)

POAI's stock peer is STSS (Sharps Technology, Inc.)

POAI's stock peer is STXS (Stereotaxis, Inc.)

POAI's stock peer is ZJYL (Jin Medical International Ltd.)

Healthcare Medical - Instruments & Supplies

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

60%

Dcf Rating

100%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

20%

Price To Earnings

20%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Recent News

Court Denies Renovaro Motion for an Expedited Trial in July

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.

2025-05-27 08:35:00

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the companies entered into a legally binding Letter Agreement pursuant to which Predictive Oncology would merge into Renovaro in exchange for a newly created class of preferred stock.

2025-05-22 15:12:00

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

2025-05-22 11:05:00

AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition

Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples

2025-05-22 08:15:00

Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health"

Latest developments expand Predictive's AI-driven drug discovery platform to include biomarker discovery and drug repurposing

2025-05-20 08:30:00

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter.

2025-05-15 07:00:00

Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended December 31, 2024, and provided a corporate update. The Company reported a loss from continuing operations of approximately $10.8 million on total revenue of $1.6 million for the year ended December 31, 2024.

2025-04-01 07:00:00

Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan

2025-03-25 07:00:00

Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries

Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth

2025-03-20 07:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions